BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17669010)

  • 21. Designing and building the next generation of improved vaccine adjuvants.
    Brito LA; O'Hagan DT
    J Control Release; 2014 Sep; 190():563-79. PubMed ID: 24998942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel strategies using DNA for the induction of mucosal immunity.
    McCluskie MJ; Davis HL
    Crit Rev Immunol; 1999; 19(4):303-29. PubMed ID: 10530431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvants for Animal Vaccines.
    Burakova Y; Madera R; McVey S; Schlup JR; Shi J
    Viral Immunol; 2018; 31(1):11-22. PubMed ID: 28618246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Adjuvants and Immunomodulators for Veterinary Vaccines.
    Heegaard PM; Fang Y; Jungersen G
    Methods Mol Biol; 2016; 1349():63-82. PubMed ID: 26458830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.
    Wang X; Meng D
    Protein Cell; 2015 Mar; 6(3):170-84. PubMed ID: 25503634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
    Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():615240. PubMed ID: 33679703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
    Garçon N; Chomez P; Van Mechelen M
    Expert Rev Vaccines; 2007 Oct; 6(5):723-39. PubMed ID: 17931153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fully mobilizing host defense: building better vaccines.
    Raychaudhuri S; Rock KL
    Nat Biotechnol; 1998 Nov; 16(11):1025-31. PubMed ID: 9831030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentiation of the activity of mucosal vaccines by immunological adjuvants.
    Dima VF; Balotescu C; Dima SV
    Roum Arch Microbiol Immunol; 2000; 59(3):157-210. PubMed ID: 11850877
    [No Abstract]   [Full Text] [Related]  

  • 31. New insights in mucosal vaccine development.
    Pavot V; Rochereau N; Genin C; Verrier B; Paul S
    Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An overview of adjuvant formulations and delivery systems.
    García A; De Sanctis JB
    APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens?
    Romeu B; Gonzalez E; Lastre M; Pérez O
    J Drug Target; 2012 Jul; 20(6):502-8. PubMed ID: 22632258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The path forward.
    De Gregorio E
    Vaccine; 2015 Jun; 33 Suppl 2():B60-3. PubMed ID: 26022572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomaterials as vaccine adjuvants.
    Jones KS
    Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
    Ahlers JD; Belyakov IM
    Eur J Immunol; 2009 Oct; 39(10):2657-69. PubMed ID: 19609978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivery strategies to enhance oral vaccination against enteric infections.
    Davitt CJ; Lavelle EC
    Adv Drug Deliv Rev; 2015 Aug; 91():52-69. PubMed ID: 25817337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases.
    Baz Morelli A; Becher D; Koernig S; Silva A; Drane D; Maraskovsky E
    J Med Microbiol; 2012 Jul; 61(Pt 7):935-943. PubMed ID: 22442293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines.
    Kataoka K; Fujihashi K
    Expert Rev Vaccines; 2009 Sep; 8(9):1183-93. PubMed ID: 19722892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.